Correction to Lancet Oncol 2025; 26: 200-13

No authors listed

Published Erratum

No authors listed. Lancet Oncol. 2025 May.

. 2025 May;26(5):e238.

doi: 10.1016/S1470-2045(25)00210-4.

No abstract available

Erratum for

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, Keating MM, van Meerten T, Alvarez RF, von Keudell G, Thieblemont C, Peyrade F, Andre M, Hoffmann M, Szafer-Glusman E, Lin J, Dean JP, Neuenburg JK, Tam CS. Wang M, et al. Lancet Oncol. 2025 Feb;26(2):200-213. doi: 10.1016/S1470-2045(24)00682-X. Lancet Oncol. 2025. PMID: 39914418 Clinical Trial.